Implement Effective CMC & Analytical Comparability Studies to Maintain Safety, Consistency and Efficacy at Every Stage of Gene Therapy Manufacturing from Phase 1 to Commercialization
The Gene Therapy Comparability Summit returns for the second year providing you with all the practical insights to optimize your gene therapy comparability approach.
In the context of scaling up gene therapy development to achieve commercial goals and mounting regulatory scrutiny, the 2nd Annual Gene Therapy Comparability Summit will unite large pharma and innovative biotechs to ensure you can establish comparability at every stage of development, supporting a seamless transition to the larger scales required for commercialization.
Focused specifically on enhancing your gene therapy comparability approach, this event will ensure you can maintain safety, quality, consistency and efficacy while adapting manufacturing processes, methods and platforms, to satisfy regulatory demands and avoid costly delays to clinical programs.
Across four days of curated content, incorporating detailed case studies from leading CMC, Regulatory, Analytical and Process Development experts, this is your opportunity to gain a hands-on, practical insight into exactly what it takes to execute successful comparability studies.
Health & Safety
The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*.
For further information around Health and Safety onsite, please visit our FAQ here.
*Please note, this is subject to change at any time without prior notice.